Krypton Biomedicals Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
as on 09-07-2024
- Paid Up Capital ₹ 0.50 M
as on 09-07-2024
- Company Age 21 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 1.04 Cr
as on 09-07-2024
- Revenue -29.15%
(FY 2020)
- Profit 577.40%
(FY 2020)
- Ebitda -33.26%
(FY 2020)
- Net Worth 9.84%
(FY 2020)
- Total Assets -38.00%
(FY 2020)
About Krypton Biomedicals
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 0.50 M.
The company has closed loans amounting to ₹1.04 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Virendra Singh, Sarla Singh, and Priyanka Rathi serve as directors at the Company.
- CIN/LLPIN
U51397DL2003PTC119626
- Company No.
119626
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Mar 2003
- Date of AGM
21 Aug 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
East Delhi, Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Krypton Biomedicals Private Limited offer?
Krypton Biomedicals Private Limited offers a wide range of products and services, including Medical Laboratory Instruments, Corona Test Kit.
Who are the key members and board of directors at Krypton Biomedicals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Virendra Singh  | Director | 28-Mar-2003 | Current |
| Sarla Singh | Director | 01-Jun-2003 | Current |
| Priyanka Rathi | Director | 01-Dec-2011 | Current |
Financial Performance of Krypton Biomedicals.
Krypton Biomedicals Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 29.15% decrease. The company also saw a substantial improvement in profitability, with a 577.4% increase in profit. The company's net worth moved up by a moderate rise of 9.84%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Krypton Biomedicals?
In 2020, Krypton Biomedicals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 16 Sep 2006 | ₹1.00 Cr | Satisfied |
Punjab National Bank Creation Date: 23 Oct 2003 | ₹0.40 M | Satisfied |
How Many Employees Work at Krypton Biomedicals?
Unlock and access historical data on people associated with Krypton Biomedicals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Krypton Biomedicals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Krypton Biomedicals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
